🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Crude Oil Down 1%; Charles Schwab Sales Top Estimates

Published 15/04/2024, 17:02
© Reuters.  Crude Oil Down 1%; Charles Schwab Sales Top Estimates
SCHW
-

Benzinga - by Avi Kapoor, Benzinga Staff Writer.

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 100 points on Monday.

The Dow traded up 0.35% to 38,114.61 while the NASDAQ rose 0.07% to 16,187.02. The S&P 500 also rose, gaining, 0.26% to 5,136.94.

Check This Out: Best Buy, Box And 2 Other Stocks Insiders Are Selling

Leading and Lagging Sectors

Health care shares jumped by 0.7% on Friday.

In trading on Friday, real estate shares fell by 1.1%.

Top Headline

Charles Schwab Corporation (NYSE: SCHW) reported better-than-expected first-quarter earnings on Monday.

Charles Schwab reported a first-quarter 2024 adjusted net income decline of 17% Y/Y to $1.469 billion. Adjusted EPS fell 20% Y/Y to 74 cents, which came in line with the consensus. Revenue fell 7% to $4.74 billion, marginally beating the consensus of $4.71 billion.

Equities Trading UP

Soligenix, Inc. (NASDAQ: SNGX) shares shot up 49% to $0.5802 after the company announced that it was granted orphan drug designation to the active ingredient in MarVax for the prevention and post-exposure prophylaxis against MARV infection by the FDA.

Shares of Longeveron Inc. (NASDAQ: LGVN) got a boost, surging 52% to $2.5650 following insider buys from multiple company executives.

Snap One Holdings Corp. (NASDAQ: SNPO) shares were also up, gaining 30% to $10.61 after the company announced that it will be acquired by Resideo Technologies.

Equities Trading DOWN

Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) shares dropped 79% to $1.5792 after the company provided an update on the Phase 3 RAISE trial and reported preliminary first-quarter financial results.

Shares of Neumora Therapeutics, Inc. (NASDAQ: NMRA) were down 14% to $11.67 after the FDA placed a clinical hold on the company's Phase 1 NMRA-266 study.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) was down, falling 10% to $42.46 after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms.

Also Check This Out: Wall Street's Most Accurate Analysts' Views On 3 Tech Stocks With Over 4% Dividend Yields

Commodities

In commodity news, oil traded down 1.3% to $84.55 while gold traded down 0.5% at $2,362.00.

Silver traded up 0.8% to $28.55 on Friday, while copper rose 1.7% to $4.3315.

Euro zone

European shares were mostly higher today. The eurozone’s STOXX 600 rose 0.06%, London’s FTSE 100 fell 0.48% while Spain’s IBEX 35 Index fell 0.11% The German DAX gained 0.39% French CAC 40 climbed 0.31% while Italy’s FTSE MIB Index jumped 0.45%.

Industrial production in the eurozone increased by 0.8% month-over-month in February.

Asia Pacific Markets

Asian markets closed mostly lower on Monday, with Japan’s Nikkei 225 falling 0.74%, Hong Kong’s Hang Seng Index dropping 0.72%, China’s Shanghai Composite gaining 1.26% and India’s S&P BSE Sensex dipping 1.14%.

Indian merchandise trade deficit shrank to $15.6 billion in March versus a year-ago gap of $18.1 billion, while wholesale prices rose by 0.53% year-over-year in March versus a 0.20% gain in the prior month.

Economics

The NY Empire State Manufacturing Index climbed to -14.3 in April versus prior month’s reading of -20.9.

Retail sales increased 0.7% month-over-month in March following a revised 0.9% rise in February.

The NAHB/Wells Fargo Housing Market Index in came in unchanged at 51.0 in April.

Total business inventories increased by 0.4% month-over-month in February, versus market expectations of a 0.3% rise.

Now Read This: Bitcoin Surpasses $66,000; Core Emerges As Top Gainer

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.